Full Breakdown
STAT’s ESMO 2026 Newsletter Highlights Day-2 of the European Cancer Conference
By Drooid · · How we work
Event Overview
The European Society for Medical Oncology’s (ESMO) annual meeting is in its second day in Madrid, drawing close to 40,000 participants from around the globe. STAT News provides a concise “ESMO in 30 Seconds” newsletter that distills the day’s key announcements and data releases for readers who cannot attend in person. The newsletter notes that a live “STAT Recap” will be streamed on Thursday, offering a real-time summary and a chance for audience questions.
Key Contributors
- Adam Feuerstein – senior writer and biotech columnist at STAT News, co-host of the weekly podcast *The Readout Loud* and author of the newsletter *Adam’s Biotech Scorecard*.
- Andrew – an unnamed contact reachable via the Signal messaging app (username drewqjoseph.71) who is listed as a confidential source for the newsletter.
Both individuals are positioned as primary points of contact for readers seeking additional information or clarification about the coverage.
Coverage Format
STAT’s newsletter is delivered electronically to subscribers and includes brief summaries of the most noteworthy scientific presentations, trial data, and regulatory updates presented at ESMO. The “ESMO in 30 Seconds” format is designed for rapid consumption, with a promise to answer reader questions during the upcoming live recap session. No verbatim quotations from speakers are provided in the newsletter; all content is paraphrased by the editorial team.
Attendance Figure
The conference’s reported attendance of “nearly 40,000 people” underscores its status as one of the largest gatherings of oncology professionals worldwide, providing a broad platform for the dissemination of new cancer research and therapeutic advances.
How to Stay Updated
Readers can subscribe to the STAT newsletter for ongoing ESMO coverage and join the Thursday live recap to receive real-time analysis and to submit questions directly to the STAT team. Contact information for the two primary contributors is provided for confidential inquiries.